Page last updated: 2024-10-29

iohexol and Carcinoma, Islet Cell

iohexol has been researched along with Carcinoma, Islet Cell in 1 studies

Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.

Carcinoma, Islet Cell: A primary malignant neoplasm of the pancreatic ISLET CELLS. Usually it involves the non-INSULIN-producing cell types, the PANCREATIC ALPHA CELLS and the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS) in GLUCAGONOMA and SOMATOSTATINOMA, respectively.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fuhrman, GM1
Charnsangavej, C1
Abbruzzese, JL1
Cleary, KR1
Martin, RG1
Fenoglio, CJ1
Evans, DB1

Other Studies

1 other study available for iohexol and Carcinoma, Islet Cell

ArticleYear
Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms.
    American journal of surgery, 1994, Volume: 167, Issue:1

    Topics: Adenocarcinoma; Carcinoma, Islet Cell; Evaluation Studies as Topic; Female; Humans; Iohexol; Male; M

1994